Overview
Lobbying Costs
800,000€ - 899,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
1.9 Fte (7)
Lobbyists with EP accreditation
6
High-level Commission meetings
18
Lobbying Costs over the years
-
Info
Eli Lilly and Company (Lilly)
EU Transparency Register
04657143399-39 First registered on 02 Apr 2010
Goals / Remit
Lilly is a leading innovative biopharmaceutical company that unites caring with discovery to make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Headquartered in the US, Lilly has more than 42,978 employees worldwide. In 2023 global revenue was approx. $34.12 billion, of which 27.3% were invested in R&D. Average cost to discover and develop a new drug: $2.6 billion. Average length of time from discovery to patient: 10 years.
( https://investor.lilly.com/financials.cfm )Main EU files targeted
EU Pharmaceutical Strategy, EU pharmaceutical legislation, Intellectual Property Rights and incentives - including Orphan Medicinal Products, Paediatric medicines and Anti-Microbial Resistance (AMR), Free Trade Agreements - EU/US, EU/UK, EU Beating Cancer Plan, EU HTA Regulation, EU Green Deal, Pharmaceuticals in the environment (PIE), the Circular Economy, Climate change, Energy taxes, European Chemicals Agency (ECA), Packaging and Packaging Waste Regulation, REACH, Urban Waste Water Treatment Directive, per-and polyfluoroalkyl substances (PFAS), Industrial strategy (including bio-manufacturing), Competition law, Horizon Europe, Innovative Healthcare Initiative (IHI), European Medicines Agency (EMA), Clinical Trials Regulation, Medical Devices Regulation, Falsified Medicines Directive, Cross-border Healthcare Directive, Data Protection Regulation, Public Procurement Directive, Substances of Human Origin (SoHO), Transparency Directive, Artificial intelligence, Digital / Digital health, European Health Data Space. Other policy areas of interest include Innovation, Research and Development, Public-Private Partnerships, Mergers and acquisitions, Life sciences, Biopharmaceuticals, Manufacturing including Active Pharmaceutical Ingredients (API), Health outcomes, Real world evidence, Pricing, reimbursement and market access to medicines, Alzheimer's research, cancer, diabetes, immunology, obesity, pain, healthcare sustainability, global health pandemics, clinical trials transparency, patient advocacy group payments, transfers of value to healthcare professionals and healthcare organisations.
Address
Head Office
Lilly Corporate Center Indianapolis Indiana
Indianapolis 46285
UNITED STATESEU Office
Rue du Marquis 1/4B Markiesstraat
Brusselles / Brussel B-1000
BELGIUMWebsite
-
People
Total lobbyists declared
7
Employment time Lobbyists 50% 3 10% 4 Lobbyists (Full time equivalent)
1.9
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
6 accreditations were / are live (in bold) for the selected state of 27 Apr 2024
Name Start date End Date Ludovica FLORENZANO 04 Apr 2024 02 Oct 2024 Maurizio GUIDI 15 Dec 2023 13 Dec 2024 Antonella ETTORRE 15 Dec 2023 13 Dec 2024 Fanny VERSPEELT 16 Feb 2024 14 Feb 2025 Aoife GALLAGHER 15 Dec 2023 13 Dec 2024 Doris SCHERNHAMMER 15 Dec 2023 13 Dec 2024 Ms Fanny VERSPEELT 16 Feb 2024 15 Apr 2024 Mr Pierluca ARIETTI 16 Dec 2023 21 Mar 2024 Mr Maurizio GUIDI 15 Dec 2023 15 Apr 2024 Ms Antonella ETTORRE 15 Dec 2023 15 Apr 2024 Ms Aoife Gallagher 15 Dec 2023 15 Apr 2024 Ms Doris Schernhammer 15 Dec 2023 15 Apr 2024 Ms Aoife Gallagher 25 Jan 2023 15 Dec 2023 Ms Doris Schernhammer 25 Jan 2023 15 Dec 2023 Ms Antonella ETTORRE 24 Jan 2023 15 Dec 2023 Mr Goncalo FERREIRA-PINTO-MENDES 24 Nov 2022 06 May 2023 Mr Pierluca ARIETTI 19 Nov 2022 18 Nov 2023 Mr Maurizio GUIDI 19 Nov 2022 18 Nov 2023 Ms Sonia Ujupan 24 Sep 2022 23 Sep 2023 Mr Goncalo PINTO MENDES 20 Oct 2021 20 Oct 2022 Ms Doris Schernhammer 13 May 2021 13 May 2022 Ms Aoife Gallagher 11 May 2021 11 May 2022 Ms Sonia Ujupan 05 Mar 2021 05 Mar 2022 Mr Gerd KRAH 27 Feb 2020 27 Feb 2021 Ms Sonia Ujupan 05 Feb 2020 05 Feb 2021 Ms Aoife Gallagher 03 Oct 2019 03 Oct 2020 Ms Arantzazu MUGICA GOICOECHEA 30 Mar 2019 01 Apr 2020 Ms Sonia Ujupan 28 Nov 2018 19 Nov 2019 Ms Doris Schernhammer 10 Nov 2018 09 Nov 2019 Mr Davide RUFFO 09 Nov 2018 09 Nov 2019 Ms Aoife Gallagher 24 May 2018 24 May 2019 Ms Sonia Ujupan 13 Nov 2017 20 Oct 2018 Ms Doris Schernhammer 01 Nov 2017 31 Oct 2018 Ms Doris Schernhammer 22 Nov 2016 01 Nov 2017 Ms Aoife Gallagher 22 Nov 2016 19 Nov 2017 Ms Sonia Ujupan 16 Nov 2016 13 Nov 2017 Ms Elisa Irlandese 15 Sep 2016 14 Sep 2017 Mr Olivier ESPEISSE 14 Jan 2016 13 Jan 2017 Ms Doris Schernhammer 13 Jan 2016 22 Nov 2016 Ms Athanasia Kanli 17 Nov 2015 12 Nov 2016 Ms Aoife Gallagher 23 Jul 2015 20 Jul 2016 Ms Doris Schernhammer 27 Jan 2015 13 Jan 2016 Ms Athanasia Kanli 10 Dec 2014 17 Nov 2015 Mr Alexander Josef ANTON 04 Apr 2013 19 Nov 2013 Mr Hugh Thomas PULLEN 26 Mar 2013 23 Mar 2014 Mr Alexander Josef ANTON 24 Feb 2012 01 Mar 2013 Mr Hugh Thomas PULLEN 24 Feb 2012 01 Mar 2013 Complementary Information
Note: 3 colleagues are full-time engaged in the Brussels office and will spend approximately 30% - 50% of their time on relevant EU affairs, with another in the Brussels office and 4 outside the Brussels office. A few other colleagues whereas spend a fraction of their time (<5%).
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
Eli Lilly and Company is a member of the following associations and bodies: European Federation of Pharmaceutical Industries and Associations (EFPIA), The European Association of Bioindustries (EuropaBio), American Chamber of Commerce to the European Union (AmChamEU), American European Community Association, Kangaroo Group, European Business Summit, Belgian Brain Council, ABC Global Alliance, Transforming Breast Cancer Together, Pharmaceutical Research and Manufacturers of America (PhRMA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
800,000€ - 899,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount concilius 50,000€ - 99,999€ covington & burling llp 50,000€ - 99,999€ vulcan consulting limited 50,000€ - 99,999€ acumen public affairs 50,000€ - 99,999€ fti consulting 10,000€ - 24,999€ rud pedersen public affairs brussels 0€ - 10,000€ fleishman-hillard 25,000€ - 49,999€ Intermediaries for current year
Name fleishman-hillard fti consulting acumen public affairs covington & burling llp concilius Closed year Costs
800,000€ - 899,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Represented through several trade bodies and industry associations, for example EFPIA, EuropaBio, AmChamEU. Participating in events on trade, industrial, health and life science policy, for example European Health Summit, Kangaroo Group and The Parliament magazine debates. Meeting with policy makers in the EU institutions. Engaging with other public policy stakeholders.
Other activities
None declared
Meetings
Meetings
18 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 06 Mar 2023 Location Brussels Subject Pharma package Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Kevin Keary (Cabinet member)
Other Lobbyists -
Date 10 Feb 2023 Location Brussels Subject Discussion of upcoming pharmaceutical package; value of predictability (IP), EU pharmaceutical product approval process, competitiveness, unmet medical needs. Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Patricia Reilly (Cabinet member)
Other Lobbyists -
Date 07 Sep 2022 Location Brussels Subject Extension of the so-called ‘TRIPS waiver’ mechanism to therapeutics & diagnostics Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Caroline Boeshertz (Cabinet member)
-
Date 22 Jun 2021 Location Brussels Subject Current trade policy issues EU-US trade relations Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Cristina Rueda Catry (Cabinet member)
- Michael Hager (Cabinet member)
-
Date 05 Feb 2020 Location Brussels Subject Discussion on Cancer and Europe's Beating Cancer Plan Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Tove Ernst (Cabinet member)
- Stella Kyriakides (Commissioner)
Other Lobbyists -
Date 06 Sep 2018 Location Brussels Subject Intellectual property incentives framework in the EU, investment and innovation Cabinet Cabinet of Vice-President Jyrki Katainen Portfolio Jobs, Growth, Investment and Competitiveness Attending - Jyrki Katainen (Vice-President)
-
Date 06 Sep 2018 Location Brussels Subject eHealth Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Digital Economy and Society Attending - Manuel Mateo-Goyet (Cabinet member)
-
Date 06 Sep 2018 Location Brussels Subject Current EU-US Trade relations; China; intellectual property rights Cabinet Cabinet of Vice-President Cecilia Malmström Portfolio Trade Attending - Maria Asenius (Cabinet member)
-
Date 29 Nov 2017 Location Brussels Subject Pharmaceutical incentives, antimicrobial resistance Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)
- Vytenis Andriukaitis (Commissioner)
Other Lobbyists -
Date 15 Jun 2016 Location Brussels Subject REACH Cabinet Cabinet of Vice-President Jyrki Katainen Portfolio Jobs, Growth, Investment and Competitiveness Attending - Hilde Hardeman (Cabinet member)
- Marika Lautso-Mousnier (Cabinet member)
-
Date 15 Jun 2016 Location BERL 08/318 Subject Interservice consultation on a substance used for disinfection in pharma processes called Triton X100 Cabinet Cabinet of Commissioner Phil Hogan Portfolio Agriculture & Rural Development Attending - Dermot Ryan (Cabinet member)
-
Date 09 Mar 2016 Location BERL 08/318 Subject Lilly /Elanco footprint and vision / mission / Hunger / Feeding the world/ How it fits with EU exporting its agriculture Cabinet Cabinet of Commissioner Phil Hogan Portfolio Agriculture & Rural Development Attending - Dermot Ryan (Cabinet member)
-
Date 03 Mar 2015 Location Brussels Subject Animal Health and Welfare, Food Security Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Marco Valletta (Cabinet member)
-
Date 06 Feb 2015 Location Brussels Subject Access to innovative medicine Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)
-
Date 21 Jan 2015 Location Brussels Subject Intro meeting Cabinet Cabinet of Commissioner Elżbieta Bieńkowska Portfolio Internal Market, Industry, Entrepreneurship and SMEs Attending - Rolf Carsten Bermig (Cabinet member)
-
Date 03 Dec 2014 Location BERL 08/318 Subject Sustainable agriculture contributing to economic growth Cabinet Cabinet of Commissioner Phil Hogan Portfolio Agriculture & Rural Development Attending - Dermot Ryan (Cabinet member)
-
Date 02 Dec 2014 Location Brussels Subject Life sciences contribution to growth and jobs Cabinet Cabinet of Vice-President Jyrki Katainen Portfolio Jobs, Growth, Investment and Competitiveness Attending - Heidi Jern (Cabinet member)